In clinical trials, whilst patients from several tumor types have shown responses to MEK inhibitor monotherapy, other patients' tumors, particularly non-small cell lung cancers, are inherently resistant to MEK inhibition. The gene discussed is MAP2K7; the disease is neoplasm.